12 Best Growth Stocks to Buy and Hold for the Long Term

8. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

5-Year Sales Growth: 52.37%

Number of Hedge Fund Holders: 49

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a commercial-stage biopharmaceutical company that develops innovative medicines based on RNAi technology. RNAi is a Nobel Prize-winning biological process that allows for the selective silencing of specific genes, preventing the production of disease-causing proteins. The company’s pipeline is focused on three main areas, including genetic medicines for rare diseases, cardio metabolic diseases, and hepatic infectious diseases.

On March 6, Analyst Kostas Biliouris of BMO Capital maintained a Buy rating on the stock with a price target of $300. The analyst highlighted a significant increase in the sales of Amvuttra, which was recently approved for ATTR-CM. The latest IQVIA data showed a 42% week-over-week sales growth, indicating robust market uptake and positioning Amvuttra as a strong competitor against existing treatments like Attruby. During the fiscal first quarter of 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported growing its revenue by 28% year-over-year to reach $469 million. This was driven by growth in the US TTR franchise, which deals with Amvuttra. The total TTR franchise segment revenue grew by 36%, driven by the US region sales, which improved 45% on a year-over-year basis and 5% quarter-over-quarter.

The analyst also noted that Amvuttra’s US sales could surpass $300 million in the second quarter, which is notably higher than the current market consensus. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reiterated 2025 financial guidance forecasting combined net product revenues of $2.05 billion to $2.25 billion, reflecting a 31% year-over-year increase at the midpoint. It is one of the best growth stocks to buy and hold for the long term.